Anthropic reveals it is working with six organizations to develop new medicines with Claude
The company says its scientists have spent months in research partnerships with six pharmaceutical organizations and that it has already begun its own drug discovery efforts.

When people talk about artificial intelligence in medicine, the conversation tends to stop at chatbots that answer questions. Anthropic has just announced something different: its scientists have spent several months deeply involved in drug development, both alongside other organizations and on their own.
The announcement came on October 27, 2026, via the company's official account on X. According to the post, over the past few months Anthropic scientists have maintained "deep research partnerships" with six organizations developing new medicines. The company adds that it has also "started its own drug discovery efforts," meaning it isn't just supporting third parties but is exploring that territory directly.
Anthropic says that work has taught it much more about how Claude, its family of AI models, can support the different stages of drug development. The company published a blog post titled "Early progress on accelerating drug development with Claude," in which it shares initial results and explains how this work fits into its broader ambitions in the life sciences.
The only material available is the post on X, not the full text of the blog, so several questions remain open. The post does not identify the six organizations, does not say which specific stages Claude is involved in, and does not detail what those "early results" are or how they were measured. Nor does it clarify whether there will be tools or plans specifically for the pharmaceutical industry, or how available they would be. For now, these conclusions should be treated for what they are: the company's own description, without independent verification.
What is clear is the direction. Anthropic is presenting the life sciences as a front in its own right, not as just another use case for its technology. For readers in Latin America, the most useful step will be to read the full post on the company's website, check what concrete results it offers, and watch whether partners, products or access criteria emerge later on that make it possible to assess how far this is from labs and researchers in the region.
Source: Anthropic on X